Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.

Item
http://www.wikidata.org/entity/Q35030123
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosisTherapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosisAn update on the evidence base for peginterferon β1a in the treatment of relapsing-remitting multiple sclerosisEffect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis.Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis."No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.[Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis].Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis
P2860

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.

Item
http://www.wikidata.org/entity/Q35030123
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effect of peginterferon beta-1 ...... -remitting multiple sclerosis.
@ast
Effect of peginterferon beta-1 ...... -remitting multiple sclerosis.
@en
type
label
Effect of peginterferon beta-1 ...... -remitting multiple sclerosis.
@ast
Effect of peginterferon beta-1 ...... -remitting multiple sclerosis.
@en
prefLabel
Effect of peginterferon beta-1 ...... -remitting multiple sclerosis.
@ast
Effect of peginterferon beta-1 ...... -remitting multiple sclerosis.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Effect of peginterferon beta-1 ...... -remitting multiple sclerosis.
@en
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P921
P932